Starting from the observation that different MAPK inhibitors are able to restore NIS expression and/or iodine uptake in various in vitro [20] and in vivo models [22] of thyroid cancer, several studies focused on redifferentiation strategies have been undertaken in a clinical setting (reviewed in [23]). This evidence concerns the gene SLC5A5 and thyroid gland carcinoma.